HUYA Bioscience International Completes First Cohort In Phase 1 Clinical Trial Of HBI-8000 In Japan

Second cohort underway in non-Hodgkin’s lymphoma patients

San Diego, CA, USA – March 19, 2015 –HUYA Bioscience International (HUYA) has completed the first cohort in a Phase 1 clinical trial in Japan of its cancer drug HBI-8000, a novel oral histone deacetylase (HDAC) inhibitor. This follows acceptance by the Pharmaceutical and Medical Devices Agency (PMDA) of the company’s accelerated development strategy in Japan. Read more